{"id":391439,"date":"2015-03-24T00:00:00","date_gmt":"2015-03-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sprpus0115-biopharma-special-report-how-are-novel-follow-on-therapies-impacting-multiple-sclerosis-treatment-paradigms\/"},"modified":"2026-03-31T09:04:02","modified_gmt":"2026-03-31T09:04:02","slug":"sprpus0115-biopharma-special-report-how-are-novel-follow-on-therapies-impacting-multiple-sclerosis-treatment-paradigms","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sprpus0115-biopharma-special-report-how-are-novel-follow-on-therapies-impacting-multiple-sclerosis-treatment-paradigms\/","title":{"rendered":"Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States?"},"content":{"rendered":"<p>Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States? is designed to assess and quantify the market impact of the 2014 launches of Teva\u2019s Copaxone 40 mg three-times-weekly (3TW) and Biogen Idec\u2019s Plegridy for the treatment of relapsing forms of multiple sclerosis (MS). Along with trial, adoption, and uptake of these disease-modifying therapies (DMTs), the report assesses U.S. neurologists\u2019 perceptions on the uniqueness and drivers of preferential prescribing of Copaxone 40 mg 3TW and Plegridy compared with other marketed DMTs. With a potential launch of generic glatiramer acetate (GA) occurring in the next year, neurologists are also surveyed about its likely effect on MS prescribing decisions and the competitive landscape.<\/p>\n","protected":false},"template":"","class_list":["post-391439","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391439\/revisions"}],"predecessor-version":[{"id":394562,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391439\/revisions\/394562"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}